Gilenya® shown to reduce MS relapse rates

[MSUK]

Gilenya® shown to reduce MS relapse rates compared to interferons or glatiramer acetate

Novartis announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya® (fingolimod) in reducing risks of relapses compared to standard therapies. These data confirm the positive results seen in clinical trials with Gilenya, and were presented at the ongoing 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark....... Read More - http://www.ms-uk.org/gilenya